Untitled

Gold‐Enhanced Brachytherapy by a Nanoparticle‐Releasing Hydrogel and 3D‐Printed Subcutaneous Radioactive Implant Approach

“…[ 61 ] It is also listed in the US and European Pharmacopoeia as a gelling agent for vaginal formulations (a maximum permissible concentration is 50% w/w). [ 62 ] However, the mechanisms by which PF127‐alginate formulations degrade in vivo have yet to be thoroughly investigated. [ 63,64 ] PF127‐alginate hydrogel degradation depends on parameters such as components concentration, molecular weight, the viscosity and L‐guluronic acid content in alginate, the ionic cross‐linking agent and gelation rate.…”

Design, synthesis of (Z)‐3‐benzyl‐5‐((1‐phenyl‐3‐(3‐((1‐ substituted phenyl‐1H‐1,2,3‐triazol‐4‐yl)methoxy)phenyl)‐1H‐pyrazol‐4‐yl)methylene)thiazolidine‐2,4‐dione analogues as potential cytotoxic agents

“…It is ingrained in a number of clinically used drugs; a few TZD-based drugs (Troglitazone, pioglitazone, Rosiglitazone, and Darglitazone) are mentioned in Figure 1, and permutations of Troglitazone moiety have been shown in Figure 2. [11] Previously published research suggests that thiazolidinedione have shown potent cytotoxic activity due to their broad and flexible nature and also exhibit a wide range of pharmacological activities which include anti-inflammatory, [12] antidiabetic, [13] antimicrobial, [14,15] anticancer, [16,17] analgesic, [18] and antioxidant agents. [19] Hetero cyclic building blocks consist of pyrazole and triazole moieties play a significant role in modern medical chemistry due to their considerable applications in various fields.…”

Susceptibility of Chlamydia trachomatis to Excipients Commonly Used in Topical Microbicide Formulations

“…Excipients can be classified into a number of categories, including preservatives, solvents, antioxidants, and gelling agents. Although excipients are important components of topical microbicide products and are also known to possess antimicrobial activity (4,12), their activity against Chlamydia trachomatis have not yet been determined. Here we use the previously described (1,10,11) minimal cidal concentration (MCC) assay, designed to test the direct action of microbicides against the extracellular, infectious C. trachomatis elementary bodies (EBs), to measure the inherent antichlamydial activity of potential excipients for formulation of active agents into topical microbicide products.…”